TacticScaleWhat Supernus Pharmaceuticals Does & How It Makes Money (SUPN)
Updated October 2026 · reflects Supernus Pharmaceuticals's latest reported financials
Biopharma company selling treatments for brain and nervous system disorders. It earns revenue by selling its branded CNS prescription drugs in the U.S.
How Supernus Pharmaceuticals makes money
It earns revenue by selling its branded CNS prescription drugs in the U.S. through pharmaceutical wholesalers, specialty pharmacies and distributors.
What Supernus Pharmaceuticals does
Supernus Pharmaceuticals is a Rockville, Maryland-based biopharmaceutical company, incorporated in 2005, that focuses on central nervous system (CNS) diseases in the United States. Its commercial portfolio includes Qelbree, a non-stimulant ADHD treatment; the extended-release epilepsy drugs Oxtellar XR and Trokendi XR (Trokendi XR is also used for migraine prevention); Parkinson's therapies GOCOVRI, APOKYN, XADAGO and the FDA-approved ONAPGO; and MYOBLOC, a Type B toxin for cervical dystonia and chronic sialorrhea. The company sells through wholesalers, specialty pharmacies and distributors. Its pipeline includes SPN-817, a first-in-class acetylcholinesterase inhibitor in Phase 2 for epilepsy including Dravet and Lennox-Gastaut syndromes; SPN-820, in Phase 2 for treatment-resistant depression under a development agreement with Navitor; and SPN-443, a Phase 1 stimulant for ADHD.
Products & services
- Qelbree
- GOCOVRI
- Oxtellar XR
- Trokendi XR
- APOKYN
- ONAPGO
What is Supernus Pharmaceuticals worth?
On an owner-earnings DCF, Supernus Pharmaceuticals's most-likely value is about $59 versus a recent price near $43 (39% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$27) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Jiangsu Nhwa Pharmaceutical (002262.SZ) · Neurocrine Biosciences (NBIX) · Biogen (BIIB) · ACADIA Pharmaceuticals (ACAD) · Collegium Pharmaceutical (COLL)